By Judy Hanover As the market for biosimilars continues to grow, it’s become important for revenue management programs to address these new products in order to build competitive advantage.  [...]

As we close the 2nd quarter of 2020 amidst global economic uncertainty and a pandemic, life sciences companies are facing more change than ever before. In a recent study conducted by Model N, the [...]

Worldwide prescription drug sales reached $843B in 2019, and growth is accelerating with the market expected to grow at a 6% annual CAGR over the next five years.  Yet despite the promise of [...]

by Judy Hanover, Senior Director Life Science Product Marketing Recently, Model N hosted Mike Townsend, Research Director for IDC’s Worldwide Life Sciences Commercial Strategies practice. Mike [...]

For the Model N life science team, the cancellation of the proposed Safe Harbor Rule change wasn’t just a regulatory decision, it meant we needed to revamp our product planning and initiatives [...]

By Jesse Mendelsohn, VP, Model N Center of Excellence On Thursday, July 11, 2019, many of us (especially those on the west coast) woke up to news that the Trump administration had pulled the plug [...]

Biopharma manufacturers are facing an unprecedented change to operating and business models, with a proposed rule published by HHS that would eliminate rebates on prescription drugs paid by [...]

The passage of the Affordable Care Act (ACA) in 2010 turned the medical loss ratio (MLR) into a critical financial target and measure of the effectiveness of U.S. health plans.  Since 2010, the [...]